logo-loader
viewBrainStorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics looks forward to top-line results for its ALS Phase 3 program

BrainStorm Cell Therapeutics (NASDAQ:BCLI) COO and Chief Medical Officer Ralph Kern sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The biotech is focused on generating top-line results for its ALS Phase 3 and progressive MS Phase 2 trials in Q4 2020 to gain eventual commercialization of its therapy called NurOwn in ALS.

Quick facts: BrainStorm Cell Therapeutics Inc.

Price: 4.14 USD

NASDAQ:BCLI
Market: NASDAQ
Market Cap: $93.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks finish week in the red; Canaccord initiates...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was down 2.6% higher at 117.4 points. Elsewhere, the OTCQX Cannabis index fell 1.8% to 480.1 points. Buds today were Pharmacielo Ltd (CVE:PCLO), The Valens Company (CVE:VLNS) (OTCMKTS:VLNCF)....

1 day, 2 hours ago

2 min read